貝萊德世界健康科學基金 Hedged A2 港幣
以盡量提高總回報為目標。基金將不少於70%的資產投資於全球各地主要從事保健、製藥、醫學科技 及生物科技供應及開發業務的公司之股票。 本基金亦可投資於其他新興市場（例如巴西、南非及南韓）。
Xiang Liu, PhD, Director, is a member of the Health Sciences team, part of BlackRock’s Active Equity Group. He is co-portfolio manager for the Health Sciences equity portfolios and is responsible for coverage of the medical devices & supplies sector. Prior to joining BlackRock in 2008, Mr. Liu was a partner and biotech analyst at Mehta Partners. From 2002 to 2005, he was a Director in the corporate development department at Cubist Pharmaceuticals. Mr. Liu began his investment career in 2000 at the Boston Consulting Group as a Healthcare consultant. Mr. Liu earned a BS degree in Chemistry from the University of Science & Technology, China in 1993, a PhD degree in Chemistry from Yale University in 1997, and a MBA degree in finance, strategy, and accounting from the University of Chicago in 2000.
Jeffrey Lee, Director, is a member of the Health Sciences team, part of BlackRock’s Active Equity Group. He is co-portfolio manager for the Health Sciences equity portfolios and is responsible for coverage of the healthcare providers and services sector. Prior to joining BlackRock in 2011, Mr. Lee was a member of the healthcare investment team at Duquesne Capital Management where he covered provider and service companies. From 2006 to 2008, Mr. Lee was an healthcare private equity associate at Altaris Capital Partners where he sourced and analyzed equity transactions for public and private healthcare companies. Prior to 2006, Mr. Lee was an analyst at Citigroup within the healthcare finance and investment banking group where he valued and helped structured financing for managed care providers, hospital companies and other large healthcare systems. Mr. Lee earned a BA degree in economics, cum laude, from Princeton University in 2004.
Erin Xie, PhD, Managing Director and portfolio manager, is the head of the Health Sciences team, part of BlackRock’s Active Equity Group. She is the lead portfolio manager for the Health Sciences equity portfolios. Ms. Xie's service with the firm dates back to 2001, including her years with State Street Research & Management (SSRM), which merged with BlackRock in 2005. At SSRM, she was a Senior Vice President and portfolio manager responsible for managing the State Street Health Sciences Fund. Prior to joining State Street Research in 2001, Ms. Xie was a research associate with Sanford Bernstein covering the pharmaceutical industry from 1999. From 1994 until 1997, she was a post doctoral research scientist at Columbia University. Ms. Xie earned a BS degree in chemistry from Beijing University in 1988, a PhD degree in Biochemistry from the University of California, Los Angeles, in 1993 and a MBA degree from the Massachusetts Institute of Technology Sloan School of Management in 1999.